The U.S. Supreme Court has agreed to review whether MedImmune can file an antitrust lawsuit over a Genentech patent for manufactured antibodies. Genentech owned one "Cabilly" patent expiring this year and then negotiated with Celltech to obtain a second patent that does not expire until 2018, a transaction the U.S. Patent and Trademark office has temporarily rejected and that MedImmune argues violates antitrust laws.

Related Summaries